VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NameVRTXON

RankNo.3685

Market Cap$0,00

Fully Diluted Market Cap$0,00

Market Share%

Trading Vol/Market Cap (24H)%70.414.265,31

Circulation Supply1,03420946

Max Supply0

Total Supply1,03420946

Circulation Rate%

Issue Date--

The price at which the asset was first issued--

All-Time High466.35223147502205,2026-03-26

Lowest Price426.5493484981209,2026-04-07

Public BlockchainETH

IntroductionVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sector

Social Media

• Official Website
• Block Explorer

etfindex:mc_etfindex_sourceDisclaimer: Data provided by cmc and should not be considered as investment advice.